1
|
Bonelli A, Menna P, Minotti G, Angeletti S, Comandini A, Picollo R, Quarchioni E, Russo V, Salvatori E, Ferravante F, Emerenziani S, Cicala M, Muscaritoli M. Safety and tolerability of a novel oral nutritional supplement in healthy volunteers. Clin Nutr 2020; 40:946-955. [PMID: 32675020 DOI: 10.1016/j.clnu.2020.06.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 06/18/2020] [Accepted: 06/19/2020] [Indexed: 10/23/2022]
Abstract
BACKGROUND AND OBJECTIVE Foods for Special Medical Purposes (FSMPs) are formulated to support the nutritional needs of subjects with impaired capacity to ingest, digest or absorb ordinary food or nutrients. Polglumyt® is a proprietary highly purified, high quality glycogen obtained from mussels. Here we report the results of a single-center, single dose, open label, single arm study carried out to investigate acceptance (i.e. gastrointestinal tolerance and palatability), metabolic profile and safety of a low osmolarity, high-density energy Polglumyt®-based drink (the investigational product, IP) as a novel FSMP. METHODS Twelve healthy subjects received a single oral administration of the IP under fasting conditions. The study endpoints were: changes in gastrointestinal system tolerability at 3 h, 6 h and 24 h after IP intake; IP palatability evaluation; metabolic evaluation through the kinetic profile of circulating glucose, insulin and C-peptide from 0 h to 6 h after IP intake and changes from baseline in circulating triglycerides at 3 h and 6 h after IP intake. RESULTS The IP showed a good gastrointestinal tolerability and an acceptable palatability. The IP did not affect the physiological glycemic profile and the triglycerides levels 6 h after the intake. The IP was well tolerated by study subjects, with no or minor adverse events. CONCLUSIONS The study results encourage additional clinical investigations on the IP as a novel FSMP in patients with impaired digestion or gastrointestinal absorption, unable to assume an ordinary diet, e.g. patients undergoing invasive gastrointestinal surgery, elderly or oncological patients, even with certain metabolic disorders.
Collapse
Affiliation(s)
- Annalisa Bonelli
- Angelini RR&D (Research, Regulatory & Development) - Angelini S.p.A., S.Palomba-Pomezia, Rome, Italy
| | - Pierantonio Menna
- Clinical Pharmacology Unit, University Campus Bio-Medico Rome, Italy
| | - Giorgio Minotti
- Clinical Pharmacology Unit, University Campus Bio-Medico Rome, Italy
| | - Silvia Angeletti
- Unit of Clinical Laboratory Science, University Campus Bio-Medico, Rome, Italy
| | - Alessandro Comandini
- Angelini RR&D (Research, Regulatory & Development) - Angelini S.p.A., S.Palomba-Pomezia, Rome, Italy
| | - Rossella Picollo
- Angelini RR&D (Research, Regulatory & Development) - Angelini S.p.A., S.Palomba-Pomezia, Rome, Italy
| | - Elisa Quarchioni
- Angelini RR&D (Research, Regulatory & Development) - Angelini S.p.A., S.Palomba-Pomezia, Rome, Italy
| | - Vincenzo Russo
- Angelini RR&D (Research, Regulatory & Development) - Angelini S.p.A., S.Palomba-Pomezia, Rome, Italy
| | - Enrica Salvatori
- Angelini RR&D (Research, Regulatory & Development) - Angelini S.p.A., S.Palomba-Pomezia, Rome, Italy
| | | | - Sara Emerenziani
- Gastroenterology Unit, University Campus Bio-Medico, Rome, Italy
| | - Michele Cicala
- Gastroenterology Unit, University Campus Bio-Medico, Rome, Italy
| | - Maurizio Muscaritoli
- Department of Translational and Precision Medicine, Sapienza University of Rome, Italy.
| |
Collapse
|
2
|
Tellone V, Rosignoli MT, Picollo R, Dragone P, Del Vecchio A, Comandini A, Radicioni M, Leuratti C, Calisti F. Effect of 3 Single Doses of Trazodone on QTc Interval in Healthy Subjects. J Clin Pharmacol 2020; 60:1483-1495. [PMID: 32488885 PMCID: PMC7586935 DOI: 10.1002/jcph.1640] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Accepted: 04/16/2020] [Indexed: 11/18/2022]
Abstract
This study evaluated the effect of 3 doses of a trazodone hydrochloride 6% oral drops solution on the QT interval of healthy volunteers. Subjects were randomly assigned to receive a single dose of trazodone 20 mg, 60 mg, and 140 mg, moxifloxacin 400 mg, and trazodone‐matched placebo in 5 periods separated by 7‐day washouts, according to a double‐blind, crossover study design. Subjects were monitored continuously, and triplicate ECGs were extracted from baseline (predose) until 24 hours postdose. Blood samples for trazodone and moxifloxacin analyses were collected at the same time points. The concentration‐QTc relationship assessed on placebo‐adjusted change from baseline for Fridericia‐corrected QT (ΔΔQTcF) was the primary end point. ΔΔQTcF values of 4.5, 12.3, and 19.8 ms for the 20‐, 60‐, and 140‐mg doses were observed at the corresponding trazodone peak plasma concentrations. The upper bound of the 90%CI exceeded 10 ms for the 60‐ and the 140‐mg doses. Time‐matched analysis results were in line with these findings. No significant trazodone effect on heart rate or PR or QRS intervals and no clinically significant new morphological changes were present. In this moxifloxacin‐validated ECG trial, trazodone had a modest, dose‐dependent effect on cardiac repolarization, with no QTc prolongation observed with the 20‐mg dose and an effect exceeding the values set in E14 guideline with the 60‐ and 140‐mg doses. The effect on cardiac repolarization is unlikely to represent a clinical risk for ventricular proarrhythmia, but caution should be used with concomitant use of other medications that prolong QT or increase trazodone exposure.
Collapse
|
3
|
Prati F, Buonfiglio R, Furlotti G, Cavarischia C, Mangano G, Picollo R, Oggianu L, di Matteo A, Olivieri S, Bovi G, Porceddu PF, Reggiani A, Garrone B, Di Giorgio FP, Ombrato R. Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and In Vivo Activity in a Mood Disorder Model. ACS Med Chem Lett 2020; 11:825-831. [PMID: 32435391 DOI: 10.1021/acsmedchemlett.9b00633] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 03/24/2020] [Indexed: 12/12/2022] Open
Abstract
Bipolar disorders still represent a global unmet medical need and pose a requirement for novel effective treatments. In this respect, glycogen synthase kinase 3β (GSK-3β) aberrant activity has been linked to the pathophysiology of several disease conditions, including mood disorders. Therefore, the development of GSK-3β inhibitors with good in vivo efficacy and safety profile associated with high brain exposure is required. Accordingly, we have previously reported the selective indazole-based GSK-3 inhibitor 1, which showed excellent efficacy in a mouse model of mania. Despite the favorable preclinical profile, analog 1 suffered from activity at the hERG ion channel, which prevented its further progression. Herein, we describe our strategy to improve this off-target liability through modulation of physicochemical properties, such as lipophilicity and basicity. These efforts led to the potent inhibitor 14, which possessed reduced hERG affinity, promising in vitro ADME properties, and was very effective in a mood stabilizer in vivo model.
Collapse
Affiliation(s)
- Federica Prati
- Angelini Pharma S.p.A., Viale Amelia, 70, 00181 Rome, Italy
| | | | - Guido Furlotti
- Angelini Pharma S.p.A., Viale Amelia, 70, 00181 Rome, Italy
| | | | | | | | - Laura Oggianu
- Angelini Pharma S.p.A., Viale Amelia, 70, 00181 Rome, Italy
| | - Anna di Matteo
- Angelini Pharma S.p.A., Viale Amelia, 70, 00181 Rome, Italy
| | | | - Graziella Bovi
- Angelini Pharma S.p.A., Viale Amelia, 70, 00181 Rome, Italy
| | - Pier Francesca Porceddu
- D3Validation Research Line, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | - Angelo Reggiani
- D3Validation Research Line, Fondazione Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy
| | | | | | | |
Collapse
|
4
|
Oggianu L, Ke AB, Chetty M, Picollo R, Petrucci V, Calisti F, Garofolo F, Tongiani S. Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction. CPT Pharmacometrics Syst Pharmacol 2020; 9:77-86. [PMID: 31808613 PMCID: PMC7020267 DOI: 10.1002/psp4.12480] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 10/12/2019] [Indexed: 11/11/2022]
Abstract
There is a paucity of clinical trials for the treatment of pediatric insomnia. This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically‐based pharmacokinetic (PBPK) modeling. Data on the pharmacokinetics of trazodone in children are currently lacking. The interaction potential between trazodone and atomoxetine was also predicted. Doses predicted in the following age groups, with exposures corresponding to adult dosages of 30, 75, and 150 mg once a day (q.d.), respectively, were: (i) 2‐ to 6‐year‐old group, doses of 0.35, 0.8, and 1.6 mg/kg q.d.; (ii) >6‐ to 12‐year‐old group, doses of 0.4, 1.0, and 1.9 mg/kg q.d.; (iii) >12‐ to 17‐year‐old group, doses of 0.4, 1.1, and 2.1 mg/kg q.d. An interaction between trazodone and atomoxetine was predicted to be unlikely. Clinical trials based on the aforementioned predicted dosing are currently in progress, and pharmacokinetic data obtained will enable further refinement of the PBPK models.
Collapse
Affiliation(s)
- Laura Oggianu
- Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy
| | - Alice B Ke
- Simcyp Division, Certara UK, Sheffield, UK
| | | | - Rossella Picollo
- Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy
| | - Vanessa Petrucci
- Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy
| | - Fabrizio Calisti
- Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy
| | - Fabio Garofolo
- Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy
| | - Serena Tongiani
- Angelini RR&D (Research Regulatory & Development), Angelini S.p.A., S. Palomba-Pomezia, Rome, Italy
| |
Collapse
|
5
|
Tellone V, Coppola P, Ammendola M, Di Loreto G, Picollo R, Del Vecchio A, Comandini A, Garofolo F, Tongiani S. New Insights on the Pharmacokinetics of Ulifloxacin After Administration of Prulifloxacin in Patients with Mild, Moderate and Severe Renal Impairment. Drugs R D 2018; 18:237-245. [PMID: 30151791 PMCID: PMC6131124 DOI: 10.1007/s40268-018-0245-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Background The antibacterial agent prulifloxacin, a prodrug of ulifloxacin, is indicated in the treatment of acute lower urinary tract infections, acute exacerbation of chronic bronchitis and acute bacterial rhinosinusitis. Objective We aimed to provide new insights on the pharmacokinetics (PK) of ulifloxacin in patients with different degrees of renal impairment. Methods A two-site, international, open-label, parallel-group, single- and repeated-dose study was performed. The drug was administered as a single dose of 600 mg to subjects with normal renal function and patients with mild, moderate and severe renal impairment. Subsequently, the same dose was administered daily for 7 days to subjects with normal renal function and patients with mild and moderate renal impairment, while a dose of 300 mg was administered daily for 7 days to patients with severe renal impairment. Plasma and urine ulifloxacin levels were measured. Complete safety evaluation was performed. Results Exposure to ulifloxacin increased as renal function decreased due to a lower ulifloxacin clearance. Ulifloxacin PK were significantly changed only in patients with severe renal impairment. The amount of ulifloxacin excreted in urine over a 24-h dosing period was similar in subjects with normal renal function and patients with mild impaired renal function, but lower in those with moderate and severe renal impairment. Conclusion Our data show that prulifloxacin is a safe quinolone and is well tolerated in both subjects with normal renal function and patients with impaired renal function, requiring a minimal dosage adjustment only in patients with severe renal impairment.
Collapse
Affiliation(s)
- Valeria Tellone
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy.
| | - Paola Coppola
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy
| | - Marco Ammendola
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy
| | - Giorgio Di Loreto
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy
| | - Rossella Picollo
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy
| | - Alessandra Del Vecchio
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy
| | - Alessandro Comandini
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy
| | - Fabio Garofolo
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy
| | - Serena Tongiani
- Angelini S.p.A.-R&D, Angelini Research Center, Piazzale della Stazione, 00071 S. Palomba, Pomezia, Rome, Italy
| |
Collapse
|
6
|
De Benedetto M, Passali D, Tomacelli G, Ruggieri A, Rosignoli MT, Picollo R, Bellussi L, Dionisio P. Penetration of prulifloxacin into sinus mucosa of patients undergoing paranasal sinus elective endoscopic surgery. J Chemother 2012; 24:26-31. [PMID: 22546721 DOI: 10.1179/1120009x12z.0000000009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The aim of this study was to assess the concentration of ulifloxacin, the active metabolite of prulifloxacin, in sinuses mucosa and plasma of patients with chronic rhinosinusitis, requiring sinus elective endoscopic surgery. Thirty-nine patients (30 males, 9 females; age range 22-77 years) with chronic sinusitis were enrolled, 35 were treated with the investigational medication. Samples from four untreated patients were used to validate the analytical method, while four treated patients dropped out before surgery. One 600 mg prulifloxacin tablet once daily was administered for 5 days before surgery. The last dosing was scheduled from 2 to 12 hours from tissue and plasma sampling. In each patient, two samples of paranasal sinus mucosa (from ethmoid and turbinate, respectively) and one blood sample were collected. Concentrations of ulifloxacin in plasma and sinuses mucosa were measured using validated bioanalytical LC/MS/MS methods. Individual and mean ulifloxacin concentrations in tissues were always higher than the relevant plasma levels. The highest concentrations were observed between 2.5 and 4.5 hours after the last dosing in all districts. The mean tissue/plasma ratios were 2.5 and 3.0 for ethmoid and turbinate, respectively. Data expressed as Area Under the Curves (AUC±SD) showed that ulifloxacin concentrations in the ethmoid were slightly higher (18.68±6.48 μg/g*h) than in turbinate (15.00±2.89 μg/g*h), and definitely higher than in plasma (6.32±1.14 μg/ml*h). The AUC ratios between tissues and plasma were 3.0 for ethmoides and 2.4 for turbinates. One patient reported two treatment-related episodes of diarrhea, which spontaneously resolved after the drug suspension. Results from this study seem to suggest that prulifloxacin showed good distribution in sinus tissues, where it reaches concentrations significantly higher than in plasma. These findings strongly call for confirmatory clinical trials in patients with bacterial rhinosinusitis.
Collapse
|
7
|
Giberti C, Gallo F, Rosignoli MT, Ruggieri A, Barattè S, Picollo R, Dionisio P. Penetration of Orally Administered Prulifloxacin into Human Prostate Tissue. Clin Drug Investig 2009; 29:27-34. [DOI: 10.2165/0044011-200929010-00003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
8
|
Gorlero F, Lorenzi P, Rosignoli MT, Picollo R, Ruggieri A, Barattè S, Dionisio P. Penetration of Prulifloxacin into Gynaecological Tissues after Single and Repeated Oral Administrations. Drugs R D 2007; 8:373-81. [DOI: 10.2165/00126839-200708060-00005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
|
9
|
Picollo R, Brion N, Gualano V, Millérioux L, Marchetti M, Rosignoli MT, Dionisio P. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneimittelforschung 2003; 53:201-5. [PMID: 12705176 DOI: 10.1055/s-0031-1297095] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The pharmacokinetic properties and tolerability of three different strengths of prulifloxacin (CAS 123447-62-1), a new antibacterial agent prodrug of AF3013 (CAS 112984-60-8), have been investigated in a randomized, cross-over study performed in 12 Caucasian male subjects (age range 19-34 years). Prulifloxacin was administered as a single oral dose at the dosages of 300, 450 and 600 mg. Plasma concentrations of the active metabolite AF3013 were determined in blood samples collected before the administration (pre-dose) and at 15, 30, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 h after dosing. Urine samples were also collected. Determination in biological samples was performed using validated and specific HPLC methods. The following parameters were calculated: Cmax, tmax, AUC0-t, AUC0--infinity, t1/2, V/F, Aeut, CLren and fe. The analysis of variance performed on dose-normalized data after logarithmic transformation evidenced no statistically significant differences between the three doses concerning Cmax and AUC. Friedman's test applied to tmax and t1/2 did not show any statistically significant difference between doses. A significant linear relationship between doses and AUC0-infinity was detected (p < 0.05). Very high urinary concentrations and the relatively long terminal half-life (10-12 h) suggest that a once-daily application would show adequate clinical efficacy, especially in urinary infections. The safety profile of the three doses was very good.
Collapse
|
10
|
Fattore C, Cipolla G, Gatti G, Bartoli A, Orticelli G, Picollo R, Millerioux L, Ciottoli GB, Perucca E. Pharmacokinetic Interactions between Theophylline and Prulifloxacin in Healthy Volunteers. Clin Drug Investig 1998. [DOI: 10.2165/00044011-199816050-00006] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
11
|
Catanese B, Panei M, Picollo R, Martinelli B, Ciarniello MG, Baravelli S. Validation of a HPLC method for the determination of bendazac and its main metabolite 5-hydroxybendazac in human plasma. Boll Chim Farm 1992; 131:22-9. [PMID: 1622607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The purpose of this study was to validate an analytical method for the determination of bendazac and its main metabolite 5-hydroxybendazac in human plasma. The results obtained indicate that the method is reproducible, accurate, precise, sensitive and specific for the measurement of bendazac and 5-hydroxybendazac in the human plasma. Therefore it can be considered suitable for experimental purposes, routine application for drug monitoring and regulatory requirements.
Collapse
Affiliation(s)
- B Catanese
- Istituto Ricerca Francesco Angelini S.p.A., Rome, Italy
| | | | | | | | | | | |
Collapse
|
12
|
Catanese B, Picollo R, Panei M, Martinelli B, Durando L, Baravelli S. Validation of a HPLC method for the determination of bendazac and its main metabolite 5-hydroxybendazac in rabbit aqueous humor and its applicability to human aqueous. Boll Chim Farm 1991; 130:449-57. [PMID: 1809299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The purpose of this study was to validate an analytical method for the determination of bendazac and its main metabolite 5-hydroxybendazac in aqueous humor. The method was validated with rabbit aqueous but it can be used also for human aqueous since no differences between the two matrices were observed. The results obtained indicate that the method is reproducible, accurate, precise, sensitive and specific for the measurement of bendazac and 5-hydroxybendazac in the aqueous humor. Therefore it can be considered suitable for experimental purposes, drug monitoring and adequate for regulatory requirements.
Collapse
Affiliation(s)
- B Catanese
- Istituto Ricerca Francesco Angelini S.p.A., Rome, Italy
| | | | | | | | | | | |
Collapse
|
13
|
Gatzemeier U, Toomes H, Picollo R, Christoffel V, Lücker PW, Ulmer J. Single- and multiple dose pharmacokinetics of lonidamine in patients suffering from non-small-cell lung cancer. Arzneimittelforschung 1991; 41:436-9. [PMID: 1650226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Pharmacokinetic studies of lonidamine (1-[2,4-dichlorobenzyl]- 1H- indazole- 3-carboxylic acid, Doridamina: CAS 50264-69-2) in humans showed a wide variation of the plasma concentration-time profiles following a single peroral dose of 300 mg (Cmax between 6.5 and 40.9 micrograms/ml, tmax between 0.75 and 5.5 h). In order to investigate single and multiple dose pharmacokinetics after peroral administration of this chemotherapeutic compound, a study was performed involving 12 patients with non-small-cell malignancies of the lungs. Plasma and urinary concentration profiles were analyzed for determination of the pharmacokinetic parameters for lonidamine after single dose administration and in the steady state. In addition, age dependency and the presence of liver induction or inhibition was evaluated. Results indicate that steady state was reached after 2 dosing intervals of 12 h and no changes in liver metabolism or age dependent pharmacokinetics could be revealed after 4 days of multiple dose treatment.
Collapse
Affiliation(s)
- U Gatzemeier
- Department of Pneumology, Centre for Pneumology and Thoracic Surgery, Krankenhaus Grosshansdorf, Fed. Rep. of Germany
| | | | | | | | | | | |
Collapse
|
14
|
Newell DR, Mansi J, Hardy J, Button D, Jenns K, Smith IE, Picollo R, Catanese B. The pharmacokinetics of oral lonidamine in breast and lung cancer patients. Semin Oncol 1991; 18:11-7. [PMID: 2031191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The plasma levels of lonidamine have been studied in 24 breast or lung cancer patients as part of the Phase II evaluation of the drug. The pharmacokinetic studies were performed when the patients had been on oral lonidamine therapy for 27 to 47 days (mean 32 days) and the studies were conducted over a 24 hour period. Lonidamine was administered in three divided doses of 150 mg (t = 0h), 150 mg (t = 7h), and 150 mg or 300 mg (t = 14h). Plasma levels of lonidamine were determined by high-performance liquid chromatography (HPLC) with fluorescence detection. Lonidamine was detected in the plasma of all patients studied, and the absolute range for the peak plasma levels of the drug following the first and second doses were 4.6-33.8 and 4.8-33.3 micrograms/ml, respectively. The range of times after administration at which the peak occurred was 0.5 to 4.2 hours for the first dose and 0.5 to 4.1 hours for the second. The absolute range for the trough levels observed over the 24-hour study period was 1.0 to 12.6 micrograms/ml and in 19 of the patients it was possible to define the apparent half life of lonidamine that was found to be within the range 2.5 to 11.7 hours. In addition to lonidamine, a number of fluorescent components were detected in the plasma of patients following lonidamine treatment that were not detected in pretreatment plasma samples. One component, a compound that eluted from the HPLC more rapidly than lonidamine, was found in some patients to be sensitive to hydrolysis with beta-glucuronidase. Comparison of the pharmacokinetic data with patient characteristics and clinical biochemistry results failed to establish any clear relationship. Similarly there was no relationship between lonidamine pharmacokinetics and either drug-induced myalgia or testicular pain. Insufficient responses were seen in the patient group studied to allow the relationship between lonidamine pharmacokinetics and response to be evaluated.
Collapse
Affiliation(s)
- D R Newell
- Drug Development Section, Institute of Cancer Research, Sutton, Surrey, UK
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Catanese B, Barillari G, Picollo R, Corradino C. Plasma levels and metabolism of bendazac lysine salt in man. Boll Chim Farm 1986; 125:298-302. [PMID: 3814364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
16
|
Catanese B, Lagana A, Marino A, Picollo R, Rotatori M. HPLC determination of benzydamine and its metabolite N-oxide in plasma following oral administration or topical application in man, using fluorimetric detection. Pharmacol Res Commun 1986; 18:385-403. [PMID: 3737653 DOI: 10.1016/0031-6989(86)90091-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
A method for the extraction and quantification of benzydamine and its metabolite N-oxide by liquid chromatography with fluorescence detection in plasma samples is described. This method has adequate sensitivity, specificity and is reproducible. The use of the extraction column allowed a recovery of both benzydamine and its metabolite of over 97% to be obtained. The plasma levels of benzydamine and its metabolite N-oxide were studied after oral administration as sugar-coated tablets or topical application to the vaginal mucosa as a cream to 6 healthy volunteers. After topical application, the plasma concentrations of the unchanged drug and its metabolite are lower than those obtained following oral administration. These data further stress the concept that, whenever possible, topical use should be considered the treatment of choice since, along with a more selective therapy, the incidence of systemic side effects can be considerably reduced.
Collapse
|